Cite

Copy

Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

Chemotherapy Protocols for Medulloblastomas in Children

This page was last updated on May 9th, 2017

Standard-Risk Medulloblastoma

Cisplatin, lomustine, and vincristine regimen A (8 x 42 day cycles) (37)

  • Day 0 of cycle: Lomustine, 75 mg/m2 PO
  • Day 1 of cycle: Cisplatin, 75 mg/m2 IV
  • Days 1, 7, 14 of cycle: Vincristine, 1.5 mg/m2 (maximum, 2 mg) IV

Cisplatin, cyclophosphamide, and vincristine regimen B (8 x 42 day cycles) (37)

  • Day 1 of cycle: Cisplatin, 75 mg/m2 IV
  • Days 1, 7, 14 of cycle: Vincristine, 1.5 mg/m2 (maximum, 2 mg) IV
  • Days 21, 22 of cycle: Cyclophosphamide, 1000 mg/m2 IV

Topotecan during radiation, followed by four cycles of dose-intense chemotherapy for standard-risk or high-risk medulloblastomas (24. 41)

  • Day -4: Cisplatin, 75 mg/m2; vincristine 1.5 mg/m2 (maximum, 2 mg) IV
  • Day -3, Day -2: Cyclophosphamide, 2 g/ m2 IV, mesna IV by continuous infusion
  • Day 0: Infusion of peripheral blood stem cells or bone marrow
  • Day +1: G-CSF, 5 µg/kg/day SC/IV until ANC[2]>2000 / µl for 2 consecutive days after nadir
  • Day +6: Vincristine, 1.5 mg/m2 (maximum, 2 mg) IV

High-Risk Medulloblastoma

Carboplatin and vincristine during radiation, followed by maintenance: cisplatin, lomustine, vincristine, and cyclophosphamide for high-risk medulloblastoma (26)

  • 2 doses of carboplatin before radiation: The recommended phase 2 dose of carboplatin during radiation was 35 mg/m2 IV daily 1–4 hours before radiation, to a maximum total of 30 doses.
  • Vincristine during radiation: Vincristine, 1.5 mg/m2 (maximum, 2 mg) IV weekly was given during radiation for 6 weeks.
  • Maintenance: 6 cycles of cisplatin, cyclophosphamide, vincristine, every 28 days as long as counts have recovered. Cisplatin, 75 mg/ m2 IV, on day 1 is administered over 6 hours with normal saline and mannitol (7.5 g/l) at a rate of 125 ml/m2/hour. Vincristine, 1.5 mg/m2 (maximum, 2 mg), is given IV on days 1 and 8. Cyclophosphamide, 1,000 mg/m2 IV, is given over 1 hour on days 2 and 3. On the first day of administration, cyclophosphamide should be given at least 24 hours after cisplatin. Mesna, 360 mg/m2, is given IV with cyclophosphamide infusion and 3 and 6 hours after cyclophosphamide. G-CSF, 5 µg/kg/day, is given subcutaneously or IV once daily beginning 24 hours after the last dose of cyclophosphamide and continuing for at least 10 days. It is continued until post-nadir ANC > 1500/µl or a minimum of 24 hours before the next chemotherapy cycle if counts have recovered from their nadir, whichever occurs first.

Topotecan during radiation, followed by four cycles of dose-intense chemotherapy for standard-risk or high-risk medulloblastomas (24, 41)

Median cycle duration was 28 days. Each cycle consisted of the following:

  • Day -4: Cisplatin, 75 mg/m2; vincristine, 1.5 mg/m2 (maximum, 2 mg) IV
  • Day -3, Day -2: Cyclophosphamide, 2g/m2 IV; mesna IV by continuous infusion
  • Day 0: Infusion of peripheral blood stem cells or bone marrow
  • Day +1: G-CSF, 5 µg/kg/day SC/IV until ANC>2000 / µl for 2 consecutive days after nadir
  • Day +6: Vincristine, 1.5 mg/m2 (maximum, 2 mg) IV

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.